Cas:2008-39-1 2,4-D Amine manufacturer & supplier

Chemical Name:2,4-D Amine

CAS.NO:2008-39-1

Synonyms:2,3-DIMETHYLACETOPHENONE;N-Methylmethanaminium (2,4-dichlorophenoxy)acetate;(2,4-dichlorophenoxy)acetic acid – dimethylamine (1:1);demise;Dimethylamine (2,4-dichlorophenoxy)acetate;(2,4-Dichlorophenoxy)acetic acid cmpd with N-methylmethanamine (1:1);Defy;aminol;(2,4-Dichlorophenoxy)acetic acid – N-methylmethanamine (1:1);Barber’s Weed Killer;Herbitex;N-Methylmethanamine 2,4-dichlorophenoxyacetate;dimethylammonium 2,4-dichlorophenoxyacetate;dikamind;2,4-D Amine;dimethylammonium (2,4-dichlorophenoxy)acetate;hormin;C10H13Cl2NO3;Acetic acid, 2-(2,4-dichlorophenoxy)-, compd. with N-methylmethanamine (1:1);weedar96;(2,4-dichlorophenoxy)acetic acid—N-methylmethanamine;bladexg;MFCD00072481;2,4-ddma;EINECS 217-915-8;2,4-dichlorophenoxyacetic acid,dimethylammonium salt;2,4-dichlorophenoxyacetic acid dimethyl amine salt;phordene;2-(2,4-dichlorophenoxy)acetic acid compound with N-methylmethanamine (1:1)

Molecular Formula:C₁₀H₁₃Cl₂NO₃

Molecular Weight:266.121

HS Code:2922509090

Physical and Chemical Properties:

Melting point:92.8 – 93.4ºC

Boiling point:345.6ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:58.56000

Exact Mass:265.027252

LogP:2.68330

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3345

Packing Group:III

Contact us for information like 2,3-DIMETHYLACETOPHENONE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(2,4-dichlorophenoxy)acetic acid compound with N-methylmethanamine (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Methylmethanamine 2,4-dichlorophenoxyacetate Use and application,(2,4-dichlorophenoxy)acetic acid—N-methylmethanamine technical grade,usp/ep/jp grade.

Related News: At present, there are more than 8,000 domestic API manufacturers, but they mainly produce bulk APIs with low technical content. 2,4-D Amine manufacturer ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib. 2,4-D Amine supplier By recapitulating the tumor microenvironment and using a live-cell, function-first approach, Resonant��s platform generates therapeutic candidates that would not be discovered by other methods with unprecedented speed. 2,4-D Amine vendor ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib. 2,4-D Amine factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.